No Data
No Data
LifeSci Capital Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $22
12 Health Care Stocks Moving In Monday's Intraday Session
Protara Therapeutics Stock Drops Following Interim Trial Results
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings
Protara Therapeutics: Promising Clinical Progress and Strong Buy Rating Amid Encouraging ADVANCED-2 Study Results
Adria87 :


Magic 1983 : what the fuck is goin on here


